while the median survival time with treatment is approximately 9 months. Recently, the survival rate has improved in NSCLC both early and late stage. findings show

that the survival in early stage disease (stage IB-IIIB) improves

when a platinum-based chemotherapy is performed after surgical resection. In addition, targeted treatments have improved survival in patients with stage IV disease

especially in patients with EGFR mutation

Comments

Leave a Reply

Sign In

Register

Reset Password

Please enter your username or email address, you will receive a link to create a new password via email.